Skip to main content

Short Title Phase 3 Sonrotoclax + Zanubrutinib compared with Ven + Obinutuzumab in Patients untreated CLL

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

BeiGene USA, Inc.

Start Date

May 21, 2024

End Date

April 30, 2029
 

Administered By

Duke Cancer Institute

Awarded By

BeiGene USA, Inc.

Start Date

May 21, 2024

End Date

April 30, 2029